New pill shows promise for kidney disease patients
NCT ID NCT06670352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called HSK39297 in 87 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug could lower protein levels in urine, a sign of kidney damage, compared to a placebo. Participants took the drug or placebo for up to 24 weeks, and researchers measured changes in urine protein.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210000, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Atacicept's Long-Term promise for kidney disease
- Scientists investigate mysterious loin pain in kidney disease
- New hope for kidney patients: drug aims to prevent relapse
- 800-Patient study aims to uncover best treatments for kidney disease